Lisa Shulman

Lisa Shulman

Auto-generated profile, based on publicly available information

Lisa Shulman

University of Maryland School of Medicine Baltimore MD United States

Research Focus & Metrics

Academic Career Length

13Years (2014-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
14 January 2021 in Trials
Verified
Journal Article
Open access
PDF file
JOJacqueline A. Odgis
Jacqueline A. Odgis
KGKatie M. Gallagher
Katie M. Gallagher
Sabrina SuckielSabrina Suckiel
Sabrina Suckiel
KDKatherine E. Donohue
Katherine E. Donohue
MRMichelle A. Ramos
Michelle A. Ramos
EKEimear E Kenny
Eimear E Kenny
Background: Increasingly, genomics is informing clinical practice, but challenges remain for medical professionals lacking genetics expertise, and in access to and clinical utility of genomic testing for minority and underrepresented populations. The latter is a particularly pernicious problem due to the historical lack of inclusion of racially and ethnically diverse populations in genomic research and genomic medicine. A further challenge is the rapidly changing landscape of genetic tests and considerations of cost, interpretation, and diagnostic yield for emerging modalities like whole-genome sequencing. Methods: The NYCKidSeq project is a randomized controlled trial recruiting 1130 children and young adults predominantly from Harlem and the Bronx with suspected genetic disorders in three disease categories: neurologic, cardiovascular, and immunologic. Two clinical genetic tests will be performed for each participant, either proband, duo, or trio whole-genome sequencing (depending on sample availability) and proband targeted gene panels. Clinical utility, cost, and diagnostic yield of both testing modalities will be assessed. This study will evaluate the use of a novel, digital platform (GUÍA) to digitize the return of genomic results experience and improve participant understanding for English- and Spanish-speaking families. Surveys will collect data at three study visits: baseline (0 months), result disclosure visit (ROR1, + 3 months), and follow-up visit (ROR2, + 9 months). Outcomes will assess parental understanding of and attitudes toward receiving genomic results for their child and behavioral, psychological, and social impact of results. We will also conduct a pilot study to assess a digital tool called GenomeDiver designed to enhance communication between clinicians and genetic testing labs. We will evaluate GenomeDiver’s ability to increase the diagnostic yield compared to standard practices, improve clinician’s ability to perform targeted reverse phenotyping, and increase the efficiency of genetic testing lab personnel. Discussion: The NYCKidSeq project will contribute to the innovations and best practices in communicating genomic test results to diverse populations. This work will inform strategies for implementing genomic medicine in health systems serving diverse populations using methods that are clinically useful, technologically savvy, culturally sensitive, and ethically sound. Trial registration: ClinicalTrials.gov NCT03738098. Registered on November 13, 2018 Trial Sponsor: Icahn School of Medicine at Mount Sinai Contact Name: Eimear Kenny, PhD (Principal Investigator) Address: Icahn School of Medicine at Mount Sinai, One Gustave L. Levy Pl., Box 1003, New York, NY 10029 Email: eimear.kenny@mssm.edu

1 November 2014 in Parkinsonism & Related Disorders
Verified
Journal Article
Closed access
MAMelissa Armstrong
Melissa Armstrong
AGAnn Gruber-Baldini
Ann Gruber-Baldini
SRStephen G. Reich
Stephen G. Reich
PFPaul S. Fishman
Paul S. Fishman
CLChristian Lachner
Christian Lachner
LSLisa M. Shulman
Lisa M. Shulman

4 June 2021 in American Journal of Medical Genetics Part A
Verified
Journal Article
Closed access
PDF file
HHHayden A. M. Hatch
Hayden A. M. Hatch
MOMolly H. O'NEil
Molly H. O'NEil
RMRobert W. Marion
Robert W. Marion
JSJulie Secombe
Julie Secombe
LSLisa H. Shulman
Lisa H. Shulman

1 February 2020 in Neurology Clinical Practice
Verified
Journal Article
Closed access
PDF file
JMJustin Martello
Justin Martello
LSLisa M. Shulman
Lisa M. Shulman
EBErik Barr
Erik Barr
AGAnn Gruber-Baldini
Ann Gruber-Baldini
MAMelissa J. Armstrong
Melissa J. Armstrong
Background Quality measures (QMs) exist to operationalize guidelines by measuring adherence to guidelines through documentation, ultimately leading to improved patient outcomes. Studies are rare looking at the relationship between adherence to Parkinson disease (PD) QMs and patient outcomes. Methods We assessed adherence of our movement disorders specialists (MDSs) to the American Academy of Neurology9s 2010 PD QM set through chart review using the measure set work group9s criteria of documentation. We then evaluated patient outcomes to see whether there was a correlation with adherence to these QMs. Results Ninety-seven consecutive patients met the inclusion criteria. The mean disease duration was 9.3 (5.8) years. All patients were assessed by 1 of 4 MDSs. A total of 68% of QMs were documented across all patients. There was a small positive correlation between the number of documented QMs the year before the index visit and the number of calls/emails both the year before and after the index visit (r = 0.20, p = 0.04 and r = 0.26, p = 0.01, respectively.) There was a small negative correlation between the number of documented QMs and the number of PD follow-up visits the year after the index visit (r = −0.19, p = 0.05.) No other outcome showed a statistically significant correlation with the adherence to documented QMs. Conclusions We found no clinically important improvement in patient outcomes with higher adherence levels. It is important that QM developers validate QMs to ensure that they fulfill the intended goal of improved patient outcomes.

5 April 2016 in Neurology
Verified
Journal Article
Closed access
MAMelissa Armstrong
Melissa Armstrong
JVJoseph Vandigo
Joseph Vandigo
CMC. Daniel Mullins
C. Daniel Mullins
LSLisa Shulman
Lisa Shulman

15 November 2019 in Journal of Child Neurology
Verified
Journal Article
Closed access
PDF file
LSLisa Shulman
Lisa Shulman
MVMaria Rosario Valicenti-McDermott
Maria Rosario Valicenti-McDermott
RSRosa Seijo
Rosa Seijo